Pipeline-in-a-drug, page-4

TY!
I agree, and I have a firm belief that it will not be a problem.

IMHO the seeming complexities involved are exactly the sort of strategic bread-and-butter work for MT & JC that underpins their commercialisation objectives. They would be right across this stuff.
MT in particular was three steps ahead of us with that unexpected Amylyx meeting; probably remains two steps ahead of the best of us; and easily one step ahead of the rest of us mere mortals.

Unpacking the pipeline strategy, intrigues the investment analyst part of me - and there are plenty here more deeply intimate with biotech strategy -- and for me, the interplay between mechanism of action, and the price-setting aspects, were of special interest, but I await to hear the thoughts of others, to isolate their special viewpoint in this ...
cheers,
Ice